LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-24. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
=== Reductive routes === A nickel catalyst can hydrogenate unsaturated N-containing functional groups to amines. Suitable groups include nitriles, imines (including oximes), amides, azides, and nitro groups. Many amines are produced from aldehydes and ketones via reductive amination, reduction of an imine formed in situ or a two-step process. LiAlH4 is more commonly employed to reduce these groups at laboratory scale. In the case of nitriles, reactions are sensitive to acidic or alkaline conditions, which can hydrolyze the −CN group. Aniline (C6H5NH2) and derivatives are prepared by reduction of the corresponding nitroaromatics. In industry, hydrogen is the preferred reductant, whereas tin and iron are often employed in the laboratory.
According to Vandewalle, Gaddafi "dominated [Libya's] political life" during his period in power. The sociologist Raymond A. Hinnebusch described the Libyan as "perhaps the most exemplary contemporary case of the politics of charismatic leadership", displaying all of the traits of charismatic authority outlined by the sociologist Max Weber. According to Hinnebusch, the foundations of Gaddafi's "personal charismatic authority" in Libya stemmed from the blessing he had received from Nasser coupled with "nationalist achievements" such as the expulsion of foreign military bases, the extraction of higher prices for Libyan oil, and his vocal support for the Palestinian and anti-imperialist causes. A cult of personality devoted to Gaddafi existed in Libya through most of his rule. His biographer Alison Pargeter noted that "he filled every space, moulding the entire country around himself." Depictions of his face could be found throughout the country, including on postage stamps, watches, and school satchels. Quotations from The Green Book appeared on a wide variety of places, from street walls to airports and pens, and were put to pop music for public release. In private, Gaddafi often complained that he disliked this personality cult surrounding him, but that he tolerated it because the people of Libya adored him. The cult served a political purpose, with Gaddafi helping to provide a central identity for the Libyan state. Several biographers and observers characterized Gaddafi as a populist. He enjoyed attending lengthy, often televised, public sessions where he was questioned.
=== Amphibian === The unfertilized oocyte of a frog, or Xenopus laevis, has also been utilized as an expression system for heterologous expression. Initially used to express the acetylcholine receptor in 1982, since then it has been used for a variety of reasons. These oocytes are produced by frogs year round and thus are relatively abundant, and translation occurs with high fidelity. Of the many limitations to the oocyte system, one major one is that the produced heterologous proteins interact with the frog oocyte's proteins which changes its behavior compared to what it would be in a mammalian cell. Additionally, where mammals are diploid, these xenopus have four homologous copies of each chromosome and thus, proteins derived may have a different function. More research is needed to examine the protein production of X. laevis systems.
Sources: en.wikipedia.org
== Reproduction and life cycle == Most Hydras can reproduce sexually under certain conditions, though they typically choose to reproduce asexually instead. Unlike many members of the Hydrozoa, which alternate between the polyp form and the medusa form (the life stage where sexual reproduction occurs), Hydra never progress beyond the polyp phase in their life cycle. Instead, when food is plentiful, many Hydra opt to reproduce asexually by budding. A section of the body wall and an extension of the digestive cavity develop, creating a bud. The buds grow into miniature adults and break away when mature. When a Hydra is well fed, a new bud can form every two days. When conditions are harsh, often before winter or in poor feeding conditions, sexual reproduction then occurs in some Hydra. Either the ovaries or testes develop from interstitial cells of the epidermis, resulting in swellings in the body wall. The testes release free-swimming gametes into the water, and these can fertilize the egg in the ovary of another individual. The fertilized eggs secrete a tough outer coating, and, as the adult dies (due to starvation or cold), these resting eggs fall to the bottom of the lake or pond to await better conditions, whereupon they hatch into nymph Hydra. The male Hydra is typically smaller in size and bears 1 to 8 conical testes, while the female is larger and has 1 to 2 ovaries. Some Hydra species, like Hydra circumcincta and Hydra viridissima, are hermaphrodites and may produce both testes and ovaries at the same time.
In the 1970s, antineoplastic (chemotherapy) drugs were identified as hazardous, and the American Society of Health-System Pharmacists (ASHP) has since then introduced the concept of hazardous drugs after publishing a recommendation in 1983 regarding handling hazardous drugs. The adaptation of federal regulations came when the U.S. Occupational Safety and Health Administration (OSHA) first released its guidelines in 1986 and then updated them in 1996, 1999, and, most recently, 2006. The National Institute for Occupational Safety and Health (NIOSH) has been conducting an assessment in the workplace since then regarding these drugs. Occupational exposure to antineoplastic drugs has been linked to multiple health effects, including infertility and possible carcinogenic effects. A few cases have been reported by the NIOSH alert report, such as one in which a female pharmacist was diagnosed with papillary transitional cell carcinoma. Twelve years before the pharmacist was diagnosed with the condition, she had worked for 20 months in a hospital where she was responsible for preparing multiple antineoplastic drugs. The pharmacist did not have any other risk factor for cancer, and therefore, her cancer was attributed to the exposure to the antineoplastic drugs, although a cause-and-effect relationship has not been established in the literature. Another case happened when a malfunction in biosafety cabinetry is believed to have exposed nursing personnel to antineoplastic drugs. Investigations revealed evidence of genotoxic biomarkers two and nine months after that exposure.
== Awards and honors == 2024 York U Alumni Award for Outstanding Achievement 2020 Lifetime Achievement Award in Plasma Spectrochemistry 2019 HUPO Award (Human Proteome Organization) 2014 Fellow of the American Institute for Medical and Biological Engineering 2011 University of Toronto Inventor of the Year Award for Biomedical and Life Sciences 2011 Thermo Fisher Scientific Spectroscopy Award 2004 Elsevier / Spectrochimica Acta Atomic Spectroscopy Award for the most important paper published in Spectrochimica Acta Part B in 2002 (Title: Reaction cells and collision cells for ICP-MS: a tutorial review) in co-authorship with Dmitry Bandura and Vladimir Baranov 2003 W.A.E. McBryde medal from the Canadian Chemical Society of the Chemical Institute of Canada 2001 Manning Innovation Award, Award of Distinction Dr. Scott Tanner, together with Dr. Vladimir Baranov, received the Manning Award of Distinction from the Manning Innovation Awards Foundation for the remarkable invention of the ICP-MS Dynamic Reaction Cell (Collision/reaction cell). 1999 Pittcon Editors' Awards Perkin-Elmer Sciex for their ELAN 6100 DRC (Dynamic Reaction Cell) ICP-MS system. Fellow of the Royal Society of Chemistry (UK) Fellow of the American Institute for Medical and Biological Engineering (AIMBE)
== External links == "Food Packaging -- Roles, Materials, and Environmental Issues - IFT.org". www.ift.org. Retrieved 3 December 2018. Poly(hydroxyalkanoates) for Food Packaging: Application and Attempts towards Implementation
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.